Table 3

Major cardiovascular events, comparison between different bDMARDs/tsDMARDs (observational studies)

Study IDRegistryInterventionControlaHR (I vs C)Risk of bias
Major cardiovascular events
Harrold 2018
Arthritis Res Ther16
CORRONACZPOther TNFiaIRR: 1.0 (0.5; 2.1)Low
Jin 2018
J Rheumatol36
Claims databaseABATNFi 0.8 (0.7; 0.9)High
Kim 2017
Arthritis Rheumatol37
Claims databaseTCZTNFi0.8 (0.6; 1.3)High
Kim 2018
Semin Arthritis Rheum38
TCZABA0.8 (0.6; 1.2)High
Myocardial infarction
Jin 2018
J Rheumatol36
Claims databaseABATNFi 0.6 (0.4; 0.9)High
Kim 2017
Arthritis Rheumatol37
Claims databaseTCZTNFi0.7 (0.4; 1.3)High
Kim 2018
Semin Arthritis Rheum38
TCZABA1.1 (0.7; 1.9)High
Zhang 2016
Ann Rheum Dis41
Claims databaseADAABA1.2 (0.9; 1.6)High
CZP1.2 (0.8; 2.0)
ETA 1.3 (1.0; 1.8)
GOL1.1 (0.6; 2.1)
IFX 1.3 (1.0; 1.7)
RTX1.1 (0.8; 1.4)
TCZ0.9 (0.5; 1.5)
TNFi 1.3 (1.0; 1.6)
Stroke
Jin 2018
J Rheumatol36
Claims databaseABATNFi1.1 (0.8; 1.5)High
Kim 2017
Arthritis Rheumatol37
Claims databaseTCZTNFi0.9 (0.5; 1.6)High
Kim 2018
Semin Arthritis Rheum38
TCZABA0.7 (0.4; 1.4)High
Heart failure
Generali 2019
Rheumatol Int34
Claims databaseABAETA1.4 (0.6; 3.5)High
Jin 2018
J Rheumatol36
Claims databaseABATNFi0.8 (0.3; 1.9)High
Kim 2018
Semin Arthritis Rheum38
Claims databaseTCZABA1.2 (0.7; 2.0)High
Venous thromboembolism
Desai 2018
Arthritis Rheumatol33
Claims databaseTOFATNFi1.3 (0.8; 2.2)High
Jin 2018
J Rheumatol36
Claims databaseABATNFi1.3 (0.6; 2.6)High
  • Additional details in online supplementary tables S60–86.

  • ABA, abatacept; ADA, adalimumab; aHR, adjusted HR; aIRR, adjusted incidence rate ratio; bDMARDs, biologic disease-modifying antirheumatic drugs; CORRONA, Consortium of Rheumatology Researchers of North America; CZP, certolizumab pegol; ETA, etanercept; GOL, golimumab; IFX, infliximab; RTX, rituximab; TCZ, tocilizumab; TNFi, tumour necrosis factor inhibitor; TOFA, tofacitinib; tsDMARDs, target synthetic disease-modifying antirheumatic drugs.